Medrol methylprednisolone 4 mg Tablet, 21-count
Other active recalls for Methylprednisolone (different manufacturers) — 1 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Methylprednisolone is used for a very wide range of conditions — basically anything where your immune system or inflammation is causing the problem. That includes severe allergic r...
- What conditions does methylprednisolone actually treat?
- It really depends on what you're being treated for. Some people take a short course for an acute flare and then stop. Others need longer-term treatment for chronic conditions. The...
- How long will I need to take this medication?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Methylprednisolone — tap one for details:
Methylprednisolone may be associated with lower levels of 9 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 776XM7047L
Calcium stearate is a white powder derived from stearic acid and calcium. It works as a lubricant and glidant to help the medicine flow smoothly during manufacturing and prevent ingredients from sticking to equipment.
-
UNII J2B2A4N98G
Lactose is a natural sugar derived from milk. In medications, it serves as a filler and binder to add bulk and help hold tablet or capsule ingredients together during manufacturing.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
-
UNII C151H8M554
A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.291 | $6.11 / 21 tablets |
| Medicaid paysCMS SDUD · 12 mo | $4.69 | $98.45 / 21 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.3001 | $6.30 / 21 tablets |
| Medicare Part B allowsASP · J7509 | $0.160 / J7509 unit | — |
Where does this data come from?
🧾 Billing & reimbursement
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| methylprednisolone 4 mg 00904-6914-61 | Major | 100 tablets | $0.124 | AB | Availability likely | save 57% |
| Methylprednisolone 4 mg 42806-0400-01 | Epic | 100 tablets | $0.124 | AB | Availability likely | save 57% |
| Methylprednisolone 4 mg 62135-0760-01 | Chartwell | 100 tablets | $0.124 | — | Availability likely | save 57% |
| Methylprednisolone 4 mg 68084-0149-01 | American | 100 tablets | $0.124 | AB | Availability likely | save 57% |
| methylprednisolone 4 mg 68382-0916-01 | Zydus | 100 tablets | $0.124 | AB | Availability likely | save 57% |
| MethylPREDNISolone 4 mg 00603-4593-15 | Par | 21 tablets | $0.126 | AB | Availability likely | save 57% |
| Methylprednisolone 4 mg 59762-4440-02 | Mylan | 21 tablets | $0.126 | AB | Availability likely | save 57% |
| methylprednisolone 4 mg 68001-0624-01 | BluePoint | 21 tablets | $0.126 | AB | Availability likely | save 57% |
| Medrol 4 mgthis 00009-0056-04 | Pharmacia | 21 tablets | $0.291 | AB | Availability likely | — |
| MethylPREDNISolone 4 mg 55289-0649-30 | PD-Rx | 30 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 57582-0101-01 | Tianjin | 100 tablets | — | AB | FDA listed | — |
| MethylPREDNISolone 4 mg 63629-2218-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 68071-2370-01 | NuCare | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 68071-5221-01 | NuCare | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 69306-0400-21 | Doc | 21 tablets | — | AB | FDA listed | — |
| methylprednisolone 4 mg 70771-1348-01 | Zydus | 100 tablets | — | AB | FDA listed | — |
| MethylPREDNISolone 4 mg 72162-1161-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| methylprednisolone 4 mg 82804-0007-21 | Proficient | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 85509-1400-02 | PHOENIX | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 85766-0037-01 | Sportpharm | 100 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 71205-0453-21 | Proficient | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 76420-0041-21 | Asclemed | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 76420-0193-21 | Asclemed | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 63187-0160-21 | Proficient | 21 tablets | — | AB | FDA listed | — |
| MethylPREDNISolone 4 mg 63629-2226-01 | Bryant | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 80425-0230-01 | Advanced | 21 tablets | — | AB | FDA listed | — |
| methylprednisolone 4 mg 50090-3811-00 | A-S | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 80425-0231-01 | Advanced | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 80425-0255-01 | Advanced | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 50090-3094-00 | A-S | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 72189-0264-21 | Direct_Rx | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 68788-7833-02 | Preferred | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 70518-2864-00 | REMEDYREPACK | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 60760-0961-21 | St. | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 70518-4213-00 | REMEDYREPACK | 21 tablets | — | AB | FDA listed | — |
| Methylprednisolone 4 mg 85534-0035-00 | HAWAII | 21 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 00009-0056-02 | 100 TABLET in 1 BOTTLE (0009-0056-02) | $0.2454 / ea | $24.54 | 1957-10-24 | Active |
| 00009-0056-04 You're viewing this | 1 DOSE PACK in 1 CARTON (0009-0056-04) / 21 TABLET in 1 DOSE PACK | $0.2908 / ea | $6.11 | 1957-10-24 | Active |
Per ea, this pack runs about 19% above the cheapest pack (100-count, $0.2454 vs $0.2908 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 00009-0056-04?
What is the difference between NDC 00009-0056-04 and NDC 00009-0056-02?
What NDC number is used to bill for this package of Medrol methylprednisolone 4 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.
Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.
Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.
Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The initial dosage of MEDROL Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted.
If after a reasonable period of time there is a lack of satisfactory clinical response, MEDROL should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT . After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of MEDROL for a period of time consistent with the patient's condition.
If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Multiple Sclerosis: In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone). ADT ® (Alternate Day Therapy): Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning.
The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for reestablishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.
A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm.
Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenal cortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenal cortical activity.
There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of adrenal cortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadren…
⛔ Contraindications ▾
CONTRAINDICATIONS Systemic fungal infections and known hypersensitivity to components.
⚠️ Warnings ▾
WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including MEDROL, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: • Reduce resistance to new infections • Exacerbate existing infections • Increase the risk of disseminated infections • Increase the risk of reactivation or exacerbation of latent infections • Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.
The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider MEDROL withdrawal or dosage reduction as needed. Tuberculosis If MEDROL is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.
Closely monitor such patients for reactivation. During prolonged MEDROL therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including MEDROL.
In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: • If a MEDROL-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. • If a MEDROL-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including MEDROL.
Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with MEDROL. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.
Fungal Infections Corticosteroids, including MEDROL, may exacerbate systemic fungal infections; therefore, avoid MEDROL use in the presence of such infections unless MEDROL is needed to control drug reactions. For patients on chronic MEDROL therapy who develop systemic fungal infections, MEDROL withdrawal or dosage reduction is recommended. Amebiasis Corticosteroids, including MEDROL, may activate latent amebiasis.
Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating MEDROL in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including MEDROL, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
Cerebral Malaria Avoid corticosteroids, including MEDROL, in patients with cerebral malaria. Ophthalmic Effects Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corti…
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Fluid and Electrolyte Disturbances • Sodium retention • Congestive heart failure in susceptible patients • Hypertension • Fluid retention • Potassium loss • Hypokalemic alkalosis Musculoskeletal • Muscle weakness • Loss of muscle mass • Steroid myopathy • Osteoporosis • Tendon rupture, particularly of the Achilles tendon • Vertebral compression fractures • Aseptic necrosis of femoral and humeral heads • Pathologic fracture of long bones Gastrointestinal • Peptic ulcer with possible perforation and hemorrhage • Pancreatitis • Abdominal distention • Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment.
These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation. Dermatologic • Impaired wound healing • Petechiae and ecchymoses • May suppress reactions to skin tests • Thin fragile skin • Facial erythema • Increased sweating Neurological • Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment • Convulsions • Vertigo • Headache Endocrine • Development of Cushingoid state • Suppression of growth in children • Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness • Menstrual irregularities • Decreased carbohydrate tolerance • Manifestations of latent diabetes mellitus • Increased requirements of insulin or oral hypoglycemic agents in diabetics Ophthalmic • Posterior subcapsular cataracts • Increased intraocular pressure • Glaucoma • Exophthalmos Metabolic • Negative nitrogen balance due to protein catabolism Vascular • Flushing The following additional reactions have been reported following oral as well as parenteral therapy: Urticaria and other allergic, anaphylactic or hypersensitivity reactions.
🔄 Drug Interactions ▾
DRUG INTERACTIONS The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.
Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
🤰 Pregnancy ▾
Usage in Pregnancy Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED MEDROL Tablets are available in the following strengths and package sizes: 2 mg (white, elliptical, scored, imprinted MEDROL 2) Bottles of 100 NDC 0009-0020-01 4 mg (white, elliptical, scored, imprinted MEDROL 4) Bottles of 100 NDC 0009-0056-02 DOSEPAK ™ Unit of Use (21 tablets) NDC 0009-0056-04 8 mg (white, elliptical, scored, imprinted MEDROL 8) Bottles of 25 NDC 0009-0022-01 16 mg (white, elliptical, scored, imprinted MEDROL 16) Bottles of 50 NDC 0009-0073-01 32 mg (white, elliptical, scored, imprinted MEDROL 32) Bottles of 25 NDC 0009-0176-01 Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
📦 Storage and Handling ▾
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
📋 Description ▾
DESCRIPTION MEDROL Tablets contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone occurs as a white to practically white, odorless, crystalline powder.
It is sparingly soluble in alcohol, in dioxane, and in methanol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. It is practically insoluble in water. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48.
The structural formula is represented below: Each MEDROL Tablet for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. Inactive ingredients: 2 mg 4 mg and 8 mg Calcium Stearate Calcium Stearate Corn Starch Corn Starch Lactose Lactose Mineral Oil Sucrose Sorbic Acid Sucrose 16 mg and 32 mg Calcium Stearate Corn Starch Lactose Mineral Oil Sucrose ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.
Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Chemical Structure
💬 Information for Patients ▾
Information for the Patient Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.